From conception to delivery: Managing the pregnant inflammatory bowel disease patient

World Journal of Gastroenterology

Volumn 20, Issue 13, 2014, Pages 3495-3506

  Huang, Vivian W ^a   Habal, Flavio M ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Biologics; Inflammatory bowel disease; Neonatal outcomes; Pregnancy

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; SALAZOSULFAPYRIDINE; ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT;

ANASTOMOSIS; ARTICLE; BREAST FEEDING; CONCEPTION; CROHN DISEASE; DELIVERY; DISEASE ACTIVITY; FEMALE; FERTILITY; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS (TOPIC); NONHUMAN; PREGNANCY COMPLICATION; PROCTOCOLECTOMY; ULCERATIVE COLITIS; COMPLICATION; ENVIRONMENTAL EXPOSURE; GENETICS; INFLAMMATORY BOWEL DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACID; ANTI-BACTERIAL AGENTS; AZATHIOPRINE; BIOLOGICAL PRODUCTS; BREAST FEEDING; CYCLOSPORINE; FEMALE; FERTILITY; HUMANS; INFLAMMATORY BOWEL DISEASES; MATERNAL EXPOSURE; METHOTREXATE; PREGNANCY; PREGNANCY COMPLICATIONS; SULFASALAZINE;

EID: 84897529378     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i13.3495     Document Type: Article

References (154)

1. Hudson M, Flett G, Sinclair TS, Brunt PW, Templeton A, Mowat NA. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 1997; 58: 229-237. [PMID: 9252260 DOI: 10.1016/S0020-7292(97)00088-X]
2. Mañosa M, Navarro-Llavat M, Marín L, Zabana Y, Cabré E, Domènech E. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scand J Gastroenterol 2013; 48: 427-432. [PMID: 23477328 DOI: 10.3109/00365521.2013.772229]
3. Mountifield R, Bampton P, Prosser R, Muller K, Andrews JM. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 2009; 15: 720-725. [PMID: 19067431 DOI: 10.1002/ibd.20839]
4. Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 591-599. [PMID: 17206690 DOI: 10.1002/ibd.20082]
5. Selinger CP, Eaden J, Selby W, Jones DB, Katelaris P, Chapman G, McDondald C, McLaughlin J, Leong RW, Lal S. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis 2013; 7: e206-e213. [PMID: 23040449 DOI: 10.1016/ j.crohns.2012.09.010]
6. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 1984; 25: 52-56. [PMID: 6140209 DOI: 10.1136/gut.25.1.52]
7. Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut 1980; 21: 469-474. [PMID: 6107262 DOI: 10.1136/ gut.21.6.469]
8. Lindhagen T, Bohe M, Ekelund G, Valentin L. Fertility and outcome of pregnancy in patients operated on for Crohn' s disease. Int J Colorectal Dis 1986; 1: 25-27. [PMID: 3598310 DOI: 10.1007/BF01648832]
9. De Dombal FT, Burton IL, Goligher JC. Crohn's disease and pregnancy. Br Med J 1972; 3: 550-553. [PMID: 5069636 DOI: 10.1136/bmj.3.5826.550]
10. Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn's disease: a case control study by European collaborative group. Gut 1986; 27: 821-825. [PMID: 3732892 DOI: 10.1136/gut.27.7.821]
11. Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int J Colorectal Dis 1997; 12: 220-224. [PMID: 9272451 DOI: 10.1007/s003840050093]
12. Arkuran C, McComb P. Crohn's disease and tubal infertility: the effect of adhesion formation. Clin Exp Obstet Gynecol 2000; 27: 12-13. [PMID: 10758789]
13. Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006; 55: 1575-1580. [PMID: 16772310 DOI: 10.1136/gut.2005.090316]
14. Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56: 830-837. [PMID: 17185356 DOI: 10.1136/gut.2006.108324]
15. Rajaratnam SG, Eglinton TW, Hider P, Fearnhead NS. Impact of ileal pouch-anal anastomosis on female fertility: metaanalysis and systematic review. Int J Colorectal Dis 2011; 26: 1365-1374. [PMID: 21766164 DOI: 10.1007/s00384-011-1274-9]
16. Tulchinsky H, Averboukh F, Horowitz N, Rabau M, Klausner JM, Halpern Z, Dotan I. Restorative proctocolectomy impairs fertility and pregnancy outcomes in women with ulcerative colitis. Colorectal Dis 2013; 15: 842-847. [PMID: 23398672 DOI: 10.1111/codi.12171]
17. Hull TL, Joyce MR, Geisler DP, Coffey JC. Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis. Br J Surg 2012; 99: 270-275. [PMID: 22095139 DOI: 10.1002/bjs.7759]
18. Beyer-Berjot L, Maggiori L, Birnbaum D, Lefevre JH, Berdah S, Panis Y. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. Ann Surg 2013; 258: 275-282. [PMID: 23360923 DOI: 10.1097/ SLA.0b013e3182813741]
19. Bartels SA, D'Hoore A, Cuesta MA, Bensdorp AJ, Lucas C, Bemelman WA. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Ann Surg 2012; 256: 1045-1048. [PMID: 22609840 DOI: 10.1097/SLA.0b013e318250caa9]
20. Tavernier N, Fumery M, Peyrin-Biroulet L, Colombel JF, Gower-Rousseau C. Systematic review: fertility in nonsurgically treated inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 847-853. [PMID: 24004045 DOI: 10.1111/ apt.12478]
21. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TI, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991; 324: 84-88. [PMID: 1984188 DOI: 10.1056/NEJM199101103240203]
22. Orholm M, Fonager K, Sørensen HT. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3236-3238. [PMID: 10566721 DOI: 10.1111/ j.1572-0241.1999.01526.x]
23. Brant SR. Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis 2011; 17: 1-5. [PMID: 20629102 DOI: 10.1002/ibd.21385]
24. Halfvarson J. Genetics in twins with Crohn's disease: less pronounced than previously believed? Inflamm Bowel Dis 2011; 17: 6-12. [PMID: 20848478 DOI: 10.1002/ibd.21295]
25. Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease--a populationbased cohort study. Am J Obstet Gynecol 1997; 177: 942-946. [PMID: 9369849 DOI: 10.1016/S0002-9378(97)70298-9]
26. Fonager K, Sørensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998; 93: 2426-2430. [PMID: 9860403 DOI: 10.1111/j.1572-0241.1998.00698.x]
27. Nørgård B, Fonager K, Sørensen HT, Olsen J. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am J Gastroenterol 2000; 95: 3165-3170. [PMID: 11095336 DOI: 10.1111/j.1572-0241.2000.03290.x]
28. Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a populationbased cohort study. Am J Gastroenterol 2002; 97: 641-648. [PMID: 11926208 DOI: 10.1111/j.1572-0241.2002.05543.x]
29. Elbaz G, Fich A, Levy A, Holcberg G, Sheiner E. Inflammatory bowel disease and preterm delivery. Int J Gynaecol Obstet 2005; 90: 193-197. [PMID: 16043179 DOI: 10.1016/ j.ijgo.2005.06.003]
30. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007; 133: 1106-1112. [PMID: 17764676 DOI: 10.1053/j.gastro.2007.07.019]
31. Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, Politi P, Ravelli P, Imperiali G, Colombo E, Pera A, Daperno M, Carnovali M, de Franchis R, Vecchi M. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol 2007; 22: 542-549. [PMID: 17376049 DOI: 10.1111/ j.1440-1746.2006.04754.x]
32. Molnár T, Farkas K, Nagy F, Lakatos PL, Miheller P, Nyári T, Horváth G, Szepes Z, Marik A, Wittmann T. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study. Scand J Gastroenterol 2010; 45: 1302-1306. [PMID: 20602569 DOI: 10.3109/00365521.2010.503967]
33. Stephansson O, Larsson H, Pedersen L, Kieler H, Granath F, Ludvigsson JF, Falconer H, Ekbom A, Sørensen HT, Nørgaard M. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis 2011; 17: 795-801. [PMID: 20564537 DOI: 10.1002/ibd.21369]
34. Raatikainen K, Mustonen J, Pajala MO, Heikkinen M, Heinonen S. The effects of pre- and post-pregnancy inflammatory bowel disease diagnosis on birth outcomes. Aliment Pharmacol Ther 2011; 33: 333-339. [PMID: 21138456 DOI: 10.1111/j.1365-2036.2010.04538.x]
35. Dotan I, Alper A, Rachmilewitz D, Israeli E, Odes S, Chermesh I, Naftali T, Fraser G, Shitrit AB, Peles V, Reif S. Maternal inflammatory bowel disease has short and long-term effects on the health of their offspring: a multicenter study in Israel. J Crohns Colitis 2013; 7: 542-550. [PMID: 23036507 DOI: 10.1016/j.crohns.2012.08.012]
36. Nørgård B, Puho E, Pedersen L, Czeizel AE, Sørensen HT. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, casecontrol study. Am J Gastroenterol 2003; 98: 2006-2010. [PMID: 14499779]
37. Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 2004; 15: 237-241. [PMID: 15280131 DOI: 10.1080/1476705041 0001668662]
38. Bortoli A, Pedersen N, Duricova D, D'Inca R, Gionchetti P, Panelli MR, Ardizzone S, Sanroman AL, Gisbert JP, Arena I, Riegler G, Marrollo M, Valpiani D, Corbellini A, Segato S, Castiglione F, Munkholm P. Pregnancy outcome in inflammatory bowel disease: prospective European casecontrol ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther 2011; 34: 724-734. [PMID: 21815900 DOI: 10.1111/ j.1365-2036.2011.04794.x]
39. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984; 6: 211-216. [PMID: 6144706]
40. Oron G, Yogev Y, Shkolnik S, Hod M, Fraser G, Wiznitzer A, Melamed N. Inflammatory bowel disease: risk factors for adverse pregnancy outcome and the impact of maternal weight gain. J Matern Fetal Neonatal Med 2012; 25: 2256-2260. [PMID: 22524421 DOI: 10.3109/14767058.2012.684176]
41. Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 460-466. [PMID: 23855477 DOI: 10.1111/apt.12417]
42. Agret F, Cosnes J, Hassani Z, Gornet JM, Gendre JP, Lémann M, Beaugerie L. Impact of pregnancy on the clinical activity of Crohn's disease. Aliment Pharmacol Ther 2005; 21: 509-513. [PMID: 15740532 DOI: 10.1111/j.1365-2036.2005.02384.x]
43. Pedersen N, Bortoli A, Duricova D, Dinca R, Panelli MR, Gisbert JP, Zoli G, López-Sanromán A, Castiglione F, Riegler G, Annese V, Gionchetti P, Prada A, Pont ED, Timmer A, Felley C, Shuhaibar M, Tsianos EV, Dejaco C, Baert FJ, Jess T, Lebech M, Hommes DW, Munkholm P. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther 2013; 38: 501-512. [PMID: 23855425 DOI: 10.1111/apt.12412]
44. Riis L, Vind I, Politi P, Wolters F, Vermeire S, Tsianos E, Freitas J, Mouzas I, Ruiz Ochoa V, O'Morain C, Odes S, Binder V, Moum B, Stockbrügger R, Langholz E, Munkholm P. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2006; 101: 1539-1545. [PMID: 16863558 DOI: 10.1111/j.1572-0241.2006.00602.x]
45. Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981; 80: 72-76. [PMID: 6108894]
46. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 1993; 105: 1057-1060. [PMID: 8405849]
47. Diav-Citrin O, Park YH, Veerasuntharam G, Polachek H, Bologa M, Pastuszak A, Koren G. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114: 23-28. [PMID: 9428214 DOI: 10.1016/S0016-5085(98)70628-6]
48. Marteau P, Tennenbaum R, Elefant E, Lémann M, Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 1998; 12: 1101-1108. [PMID: 9845399 DOI: 10.1046/j.1365-2036.1998.00417.x]
49. Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99: 656-661. [PMID: 15089898 DOI: 10.1111/j.1572-0241.2004.04140.x]
50. Nørgård B, Pedersen L, Christensen LA, Sørensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406-1413. [PMID: 17437503 DOI: 10.1111/ j.1572-0241.2007.01216.x]
51. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008; 25: 271-275. [PMID: 18242053 DOI: 10.1016/ j.reprotox.2007.11.010]
52. Hernández-Díaz S, Su YC, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates among women of childbearing age. Reprod Toxicol 2013; 37: 1-5. [PMID: 23333816 DOI: 10.1016/ j.reprotox.2013.01.001]
53. Kelley KE, Hernández-Díaz S, Chaplin EL, Hauser R, Mitchell AA. Identification of phthalates in medications and dietary supplement formulations in the United States and Canada. Environ Health Perspect 2012; 120: 379-384. [PMID: 22169271 DOI: 10.1289/ehp.1103998]
54. van der Woude CJ, Kolacek S, Dotan I, Oresland T, Vermeire S, Munkholm P, Mahadevan U, Mackillop L, Dignass A. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010; 4: 493-510. [PMID: 21122553 DOI: 10.1016/j.crohns.2010.07.004]
55. Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol 2014; 11: 116-127. [PMID: 23897285 DOI: 10.1038/nrgastro. 2013.135]
56. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17. [PMID: 12512024 DOI: 10.1053/gast.2003.50014]
57. Langagergaard V, Pedersen L, Gislum M, Nørgard B, Sørensen HT. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: A Danish nationwide cohort study. Aliment Pharmacol Ther 2007; 25: 73-81. [PMID: 17229222 DOI: 10.1111/j.1365-2036.2006.03162.x]
58. Coelho J, Beaugerie L, Colombel JF, Hébuterne X, Lerebours E, Lémann M, Baumer P, Cosnes J, Bourreille A, Gendre JP, Seksik P, Blain A, Metman EH, Nisard A, Cadiot G, Veyrac M, Coffin B, Dray X, Carrat F, Marteau P. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60: 198-203. [PMID: 21115547 DOI: 10.1136/gut.2010.222893]
59. Shim L, Eslick GD, Simring AA, Murray H, Weltman MD. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis 2011; 5: 234-238. [PMID: 21575887 DOI: 10.1016/j.crohns.2011.01.009]
60. Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, Gomollón F, Rodrigo L, Calvet X, Esteve M, García-Planella E, García-López S, Taxonera C, Calvo M, López M, Ginard D, Gómez-García M, Garrido E, Pérez-Calle JL, Beltrán B, Piqueras M, Saro C, Botella B, Dueñas C, Ponferrada A, Mañosa M, García-Sánchez V, Maté J, Gisbert JP. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 433-440. [PMID: 23318480 DOI: 10.1038/ajg.2012.430]
61. Hutson JR, Matlow JN, Moretti ME, Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol 2013; 33: 1-8. [PMID: 23259868 DOI: 10.3109/01443615.2012.716106]
62. Mahadevan U, Martin CF, Sandler RS, Kane SV, Dubinsky M, Lewis, JD, Sandborn WJ, Sands BE. PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women with IBD Exposed to Immunomodulators and Biologic Therapy. Gastroenterology 2012; 142 Suppl 1: S149. [DOI: 10.1016/ S0016-5085(12)60561-7]
63. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 15-22. [PMID: 22434610 DOI: 10.1002/ibd.22948]
64. de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006; 101: 1390-1392. [PMID: 16771965 DOI: 10.1111/j.1572-0241.2006.00538.x]
65. Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, van der Woude CJ, de Jong DJ, Mulder CJ, van Elburg RM, van Bodegraven AA. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 2014; 63: 451-457. [PMID: 23424097]
66. Angelberger S, Reinisch W, Messerschmidt A, Miehsler W, Novacek G, Vogelsang H, Dejaco C. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis 2011; 5: 95-100. [PMID: 21453877 DOI: 10.1016/j.crohns.2010.10.005]
67. de Meij TG, Jharap B, Kneepkens CM, van Bodegraven AA, de Boer NK. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 38-43. [PMID: 23675854 DOI: 10.1111/ apt.12334]
68. Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP. The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. Aliment Pharmacol Ther 2011; 33: 707-713. [PMID: 21251032 DOI: 10.1111/j.1365-2036.2011.04577.x]
69. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131: 283-311. [PMID: 16831611 DOI: 10.1053/j.gastro.2006.04.049]
70. Beaulieu DB, Ananthakrishnan AN, Issa M, Rosenbaum L, Skaros S, Newcomer JR, Kuhlmann RS, Otterson MF, Emmons J, Knox J, Binion DG. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis 2009; 15: 25-28. [PMID: 18680195 DOI: 10.1002/ibd.20640]
71. Mylonas I. Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. Arch Gynecol Obstet 2011; 283: 7-18. [PMID: 20814687 DOI: 10.1007/ s00404-010-1646-3]
72. Koss CA, Baras DC, Lane SD, Aubry R, Marcus M, Markowitz LE, Koumans EH. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother 2012; 56: 4800-4805. [PMID: 22751543 DOI: 10.1128/AAC.06477-11]
73. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 2006; 107: 1120-1138. [PMID: 16648419 DOI: 10.1097/01.AOG.0000216197.26783.b5]
74. Bar-Oz B, Moretti ME, Boskovic R, O'Brien L, Koren G. The safety of quinolones--a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009; 143: 75-78. [PMID: 19181435 DOI: 10.1016/j.ejogrb.2008.12.007]
75. Imseis HM, Zimmerman PD, Samuels P, Kniss DA. Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: suppression by glucocorticoids and NSAIDs. Placenta 1997; 18: 521-526. [PMID: 9290146 DOI: 10.1016/0143-4004(77)90005-4]
76. Brogin Moreli J, Cirino Ruocco AM, Vernini JM, Rudge MV, Calderon IM. Interleukin 10 and tumor necrosis factor-alpha in pregnancy: aspects of interest in clinical obstetrics. ISRN Obstet Gynecol 2012; 2012: 230742. [PMID: 22462002 DOI: 10.5402/2012/230742]
77. Arsenescu R, Arsenescu V, de Villiers WJ. TNF-α and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol 2011; 106: 559-562. [PMID: 21468063 DOI: 10.1038/ajg.2011.5]
78. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005; 21: 733-738. [PMID: 15771759 DOI: 10.1111/j.1365-2036.2005.02405.x]
79. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005; 54: 890. [PMID: 15888806 DOI: 10.1136/ gut.2005.065417]
80. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 2006; 12: 827-828. [PMID: 16917239 DOI: 10.1097/00054725-200608000-00020]
81. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 1255-1258. [PMID: 17045211 DOI: 10.1016/j.cgh.2006.07.018]
82. Tursi A. Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn' s disease. Dig Liver Dis 2006; 38: 439-440. [PMID: 16563889 DOI: 10.1016/j.dld.2006.01.017]
83. Angelucci E, Cocco A, Viscido A, Caprilli R. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. Inflamm Bowel Dis 2008; 14: 435-436. [PMID: 18050300 DOI: 10.1002/ ibd.20319]
84. Aratari A, Margagnoni G, Koch M, Papi C. Intentional infliximab use during pregnancy for severe steroid-refractory ulcerative colitis. J Crohns Colitis 2011; 5: 262. [PMID: 21575893 DOI: 10.1016/j.crohns.2011.02.004]
85. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-2392. [PMID: 15571587 DOI: 10.1111/j.1572-0241.2004.30186.x]
86. Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17: 1846-1854. [PMID: 21830263 DOI: 10.1002/ibd.21583]
87. Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, Kohout P, Shonova O, Lukas M. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scand J Gastroenterol 2013; 48: 951-958. [PMID: 23834232 DOI: 10.3109/00365521.2013.812141]
88. Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol 2013; 19: 2591-2602. [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591]
89. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171]
90. Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, van der Woude CJ. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33: 1053-1058. [PMID: 21366638 DOI: 10.1111/j.1365-2036.2011.04617.x]
91. Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol 2011; 32: 93-97. [PMID: 21621603 DOI: 10.1016/j.reprotox.2011.05.009]
92. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106: 214-223; quiz 224. [PMID: 21157441 DOI: 10.1038/ajg.2010.464]
93. Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ, van der Woude CJ. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013; 11: 318-321. [PMID: 23103819 DOI: 10.1016/j.cgh.2012.10.024]
94. Kane S. Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making. Clin Gastroenterol Hepatol 2013; 11: 293-294. [PMID: 23247325 DOI: 10.1016/j.cgh.2012.11.030]
95. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-292; quiz e24. [PMID: 23200982 DOI: 10.1016/j.cgh.2012.11.011]
96. Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010; 16: 881-895. [PMID: 19885906 DOI: 10.1002/ibd.21154]
97. Paziana K, Del Monaco M, Cardonick E, Moritz M, Keller M, Smith B, Coscia L, Armenti V. Ciclosporin use during pregnancy. Drug Saf 2013; 36: 279-294. [PMID: 23516008]
98. Bertschinger P, Himmelmann A, Risti B, Follath F. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol 1995; 90: 330. [PMID: 7695771]
99. Dor R, Blanshard C. Caution with the use of cyclosporin in pregnancy. Gut 2003; 52: 1070. [PMID: 12801969 DOI: 10.1136/gut.52.7.1070-a]
100. Jayaprakash A, Gould S, Lim AG, Shehata HA. Use of cyclosporin in pregnancy. Gut 2004; 53: 1386-1387. [PMID: 15306605 DOI: 10.1136/gut.2003.036103]
101. Angelberger S, Reinisch W, Dejaco C. Prevention of abortion by ciclosporin treatment of fulminant ulcerative colitis during pregnancy. Gut 2006; 55: 1364-1365. [PMID: 16905706]
102. Reindl W, Schmid RM, Huber W. Cyclosporin A treatment of steroid-refractory ulcerative colitis during pregnancy: report of two cases. Gut 2007; 56: 1019. [PMID: 17566033 DOI: 10.1136/gut.2006.105288]
103. Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol 2008; 103: 1203-1209. [PMID: 18422816 DOI: 10.1111/ j.1572-0241.2007.01756.x]
104. Branche J, Cortot A, Bourreille A, Coffin B, de Vos M, de Saussure P, Seksik P, Marteau P, Lemann M, Colombel JF. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflamm Bowel Dis 2009; 15: 1044-1048. [PMID: 19137604 DOI: 10.1002/ibd.20858]
105. Dozois EJ, Wolff BG, Tremaine WJ, Watson WJ, Drelichman ER, Carne PW, Bakken JL. Maternal and fetal outcome after colectomy for fulminant ulcerative colitis during pregnancy: case series and literature review. Dis Colon Rectum 2006; 49: 64-73. [PMID: 16320006 DOI: 10.1007/s10350-005-0210-x]
106. Nielsen OH, Loftus EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med 2013; 11: 174. [PMID: 23902720 DOI: 10.1186/1741-7015-11-174]
107. Ilnyckyji A, Blanchard JF, Rawsthorne P, Bernstein CN. Perianal Crohn's disease and pregnancy: role of the mode of delivery. Am J Gastroenterol 1999; 94: 3274-3278. [PMID: 10566729 DOI: 10.1111/j.1572-0241.1999.01537.x]
108. Smink M, Lotgering FK, Albers L, de Jong DJ. Effect of childbirth on the course of Crohn's disease; results from a retrospective cohort study in the Netherlands. BMC Gastroenterol 2011; 11: 6. [PMID: 21269464 DOI: 10.1186/1471-230X-11-6]
109. Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women with Crohn's disease. Am J Gastroenterol 1995; 90: 1918-1922. [PMID: 7484992]
110. Meli R, Gualillo O, Raso GM, Di Carlo R. Further evidence for the involvement of prolactin in the inflammatory response. Life Sci 1993; 53: PL105-PL110. [PMID: 8341128 DOI: 10.1016/0024-3205(93)90706-9]
111. Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C. Prolactin and autoimmunity. Clin Rev Allergy Immunol 2011; 40: 50-59. [PMID: 19911311 DOI: 10.1161/CIRCGENETICS. 109.853572]
112. Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol 2005; 100: 102-105. [PMID: 15654788]
113. Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the litera- ture. World J Gastroenterol 2008; 14: 165-173. [PMID: 18186549 DOI: 10.3748/wjg.14.165]
114. Castiglione F, Diaferia M, Morace F, Labianca O, Meucci C, Cuomo A, Panarese A, Romano M, Sorrentini I, D'Onofrio C, Caporaso N, Rispo A. Risk factors for inflammatory bowel diseases according to the "hygiene hypothesis": a case-control, multi-centre, prospective study in Southern Italy. J Crohns Colitis 2012; 6: 324-329. [PMID: 22405169 DOI: 10.1016/j.crohns.2011.09.003]
115. Frolkis A, Dieleman LA, Barkema H, Panaccione R, Ghosh S, Fedorak RN, Madsen K, Kaplan GG. Environment and the inflammatory bowel diseases. Can J Gastroenterol 2013; 27: e18-e24. [PMID: 23516681]
116. Moffatt DC, Ilnyckyj A, Bernstein CN. A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am J Gastroenterol 2009; 104: 2517-2523. [PMID: 19550409 DOI: 10.1038/ajg.2009.362]
117. Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol 1987; 22: 1009-1024. [PMID: 3685876 DOI: 10.3109/00365528708991950]
118. Corrao G, Tragnone A, Caprilli R, Trallori G, Papi C, Andreoli A, Di Paolo M, Riegler G, Rigo GP, Ferraù O, Mansi C, Ingrosso M, Valpiani D. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). Int J Epidemiol 1998; 27: 397-404. [PMID: 9698126 DOI: 10.1093/ije/27.3.397]
119. Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol 2010; 25: 325-333. [PMID: 20074146 DOI: 10.1111/ j.1440-1746.2009.06140.x]
120. Hansen TS, Jess T, Vind I, Elkjaer M, Nielsen MF, Gamborg M, Munkholm P. Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohns Colitis 2011; 5: 577-584. [PMID: 22115378 DOI: 10.1016/j.crohns.2011.05.010]
121. Barclay AR, Russell RK, Wilson ML, Gilmour WH, Satsangi J, Wilson DC. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr 2009; 155: 421-426. [PMID: 19464699 DOI: 10.1016/ j.jpeds.2009.03.017]
122. Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004; 80: 1342-1352. [PMID: 15531685]
123. Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet 1989; 1: 383. [PMID: 2563532 DOI: 10.1016/ S0140-6736(89)91754-6]
124. Jenss H, Weber P, Hartmann F. 5-Aminosalicylic acid and its metabolite in breast milk during lactation. Am J Gastroenterol 1990; 85: 331. [PMID: 2309691]
125. Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet 1993; 342: 618-619. [PMID: 8102746 DOI: 10.1016/0140-6736(93)91443-P]
126. Silverman DA, Ford J, Shaw I, Probert CS. Is mesalazine really safe for use in breastfeeding mothers? Gut 2005; 54: 170-171. [PMID: 15591526 DOI: 10.1136/gut.2004.048058]
127. Branski D, Kerem E, Gross-Kieselstein E, Hurvitz H, Litt R, Abrahamov A. Bloody diarrhea--a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr 1986; 5: 316-317. [PMID: 2870147 DOI: 10.1097/00005176-198605020-00028]
128. Berlin CM, Yaffe SJ. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. Dev Pharmacol Ther 1980; 1: 31-39. [PMID: 6108198]
129. Esbjörner E, Järnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 1987; 76: 137-142. [PMID: 2882643 DOI: 10.1111/ j.1651-2227.1987.tb10430.x]
130. Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28: 1209-1213. [PMID: 18761704 DOI: 10.1111/j.1365-2036.2008.03843.x]
131. Zelinkova Z, De Boer IP, Van Dijke MJ, Kuipers EJ, Van Der Woude CJ. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2009; 30: 90-1; author reply 91. [PMID: 19566905 DOI: 10.1111/j.1365-2036.2009.03996.x]
132. Moretti ME, Verjee Z, Ito S, Koren G. Breast-feeding during maternal use of azathioprine. Ann Pharmacother 2006; 40: 2269-2272. [PMID: 17132809 DOI: 10.1345/aph.1H152]
133. Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Barclay ML, Begg EJ. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006; 62: 453-456. [PMID: 16995866 DOI: 10.1111/j.1365-2125.2006.02639.x]
134. Sau A, Clarke S, Bass J, Kaiser A, Marinaki A, Nelson-Piercy C. Azathioprine and breastfeeding: is it safe? BJOG 2007; 114: 498-501. [PMID: 17261122 DOI: 10.1111/j.1471-0528.2006.01232. x]
135. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972; 112: 978-980. [PMID: 5042796]
136. Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999; 92: 551-563. [PMID: 10627876 DOI: 10.1093/ qjmed/92.10.551]
137. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108: 776-789. [PMID: 11533352]
138. Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993; 53: 324-328. [PMID: 8453851 DOI: 10.1038/clpt.1993.28]
139. Ost L, Wettrell G, Björkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr 1985; 106: 1008-1011. [PMID: 3998938 DOI: 10.1016/S0022-3476(85)80259-6]
140. Passmore CM, McElnay JC, Rainey EA, D'Arcy PF. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol 1988; 26: 45-51. [PMID: 3203060 DOI: 10.1111/j.1365-2125.1988.tb03362.x]
141. Erickson SH, Oppenheim GL, Smith GH. Metronidazole in breast milk. Obstet Gynecol 1981; 57: 48-50. [PMID: 7454176]
142. Cover DL, Mueller BA. Ciprofloxacin penetration into human breast milk: a case report. DICP 1990; 24: 703-704. [PMID: 2375140]
143. Gardner DK, Gabbe SG, Harter C. Simultaneous concentrations of ciprofloxacin in breast milk and in serum in mother and breast-fed infant. Clin Pharm 1992; 11: 352-354. [PMID: 1563233]
144. Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008; 14: 3085-3087. [PMID: 18494064 DOI: 10.3748/wjg.14.3085]
145. Ben-Horin S, Yavzori M, Katz L, Picard O, Fudim E, Chowers Y, Lang A. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010; 8: 475-476. [PMID: 20005982 DOI: 10.1016/j.cgh.2009.11.023]
146. Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, Chowers Y, Lang A. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011; 5: 555-558. [PMID: 22115374 DOI: 10.1016/j.crohns.2011.05.006]
147. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009; 43: 613-616. [PMID: 19142167 DOI: 10.1097/MCG.0b013e31817f9367]
148. Grosen A, Julsgaard M, Kelsen J, Christensen LA. Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2014; 8: 175-176. [PMID: 24090905]
149. Thiru Y, Bateman DN, Coulthard MG. Successful breast feeding while mother was taking cyclosporin. BMJ 1997; 315: 463. [PMID: 9284666 DOI: 10.1136/bmj.315.7106.463]
150. Nyberg G, Haljamäe U, Frisenette-Fich C, Wennergren M, Kjellmer I. Breast-feeding during treatment with cyclosporine. Transplantation 1998; 65: 253-255. [PMID: 9458024 DOI: 10.1097/00007890-199801270-00019]
151. Munoz-Flores-Thiagarajan KD, Easterling T, Davis C, Bond EF. Breast-feeding by a cyclosporine-treated mother. Obstet Gynecol 2001; 97: 816-818. [PMID: 11336764 DOI: 10.1016/ S0029-7844(01)01122-X]
152. Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, Verjee Z, Giesbrecht E, Koren G, Ito S. Cyclosporine excretion into breast milk. Transplantation 2003; 75: 2144-2146. [PMID: 12829927 DOI: 10.1097/01.TP.0000066352.86763.D0]
153. Osadchy A, Koren G. Cyclosporine and lactation: when the mother is willing to breastfeed. Ther Drug Monit 2011; 33: 147-148. [PMID: 21240055 DOI: 10.1097/FTD.0b013e318208e3a4]
154. Lahiff C, Moss AC. Cyclosporine in the management of severe ulcerative colitis while breast-feeding. Inflamm Bowel Dis 2011; 17: E78. [PMID: 21538721 DOI: 10.1002/ibd.21765]